The US is the only large market where generic drugs routinely cost more at the cash-pay counter than the same molecule in any other developed country. The reason is structural, not pharmacological. Five forces explain it.
The PBM middle layer
Three Pharmacy Benefit Managers, CVS Caremark, Express Scripts, and OptumRx, process roughly 80 percent of US prescription claims. They sit between manufacturers, insurers, and pharmacies. Their core revenue line is not transparency. It is the spread between what insurers pay and what pharmacies are reimbursed, plus rebates collected from manufacturers in exchange for formulary placement.
A US cash-pay consumer is outside the PBM channel entirely. They see the inflated list price that exists to support the rebate cycle, without the rebate itself flowing back to them.
Rebate-driven list pricing
Manufacturers compete for formulary tier-one placement by offering rebates against their published Wholesale Acquisition Cost. The rebate is paid back to the PBM. To preserve absolute rebate dollars, manufacturers raise the published list price each year so the rebate percentage produces a larger payment. The pattern is well documented. List prices grow. Net prices, the price the insurer actually pays after rebate, are flat or declining.
The cash-pay consumer transacts against list, not net. The structural incentive is for the gap between list and net to widen. It does, year over year.
Why generics inflate
Generic drugs in the US are subject to the same PBM channel logic. A bioequivalent generic of, say, vardenafil 20mg costs the manufacturer pennies to produce. Wholesale acquisition by US distributors, AmerisourceBergen, McKesson, Cardinal Health, adds a 2 to 5 percent margin. Chain pharmacies then layer a 30 to 80 percent cash-pay markup. Telehealth platforms that bundle a generic into a subscription can add another 5 to 30 multiple on top of that.
None of these layers exists in a market where the consumer transacts directly with a licensed pharmacy at near-acquisition cost.
What international pricing reveals
The same molecule, manufactured to the same regulatory standard, sold at one-third to one-tenth the US cash price in licensed retail in Singapore, the UK, Canada, or Australia, is not an arbitrage opportunity. It is the absence of the US channel surcharge. The international price approximates manufacturing cost plus a normal pharmacy retail margin. The US price approximates the same plus the PBM rebate machinery cost, plus distributor margin, plus chain pharmacy cash markup, plus, in many cases, telehealth packaging.
The Mispricing Index puts a number on the surcharge.
The implication for self-pay consumers
An estimated 31 million Americans are uninsured, and another 43 million are underinsured with high-deductible plans that effectively put them in the cash-pay channel for most prescriptions. For this population, transparency matters more than any other intervention. They are paying list price into a market designed around the rebate cycle they are not part of.
The PMI exists to make the cost of being a cash-pay consumer in this market visible in one number. What anyone chooses to do with that visibility is not our concern. Visibility itself is.
- FTC interim staff report on PBM concentration, 2024
- NEJM, list price vs net price divergence in branded pharmaceuticals
- Bloomberg coverage of GLP-1 cash-pay channel pricing, 2024-2026
- Wall Street Journal investigations into PBM rebate spread, 2023-2024
- ProPublica, generic drug retail markup analysis
- CMS NADAC, National Average Drug Acquisition Cost public data
This analysis describes market structure. It is not legal advice and not medical advice. We make no claim about lawful importation in any jurisdiction.